FindTrial
Sign In

Molecular typing and accurate diagnosis of intractable cases

Molecular typing and accurate diagnosis of intractable cases

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036383
Enrollment
Unknown
Registered
2020-08-22
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tumor

Interventions

Gold Standard:the pathological diagnosis after molecular detection and immunohistochemical detection
Index test:Gene&#32
sequencing&#32
results,&#32
immunohistochemical&#32
pathological&#32
diagnosis&#32
results

Sponsors

Fudan University Shanghai Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: The tumor is not clearly diagnosed (including the source, character and type of tumor), the final diagnosis can not be made directly by HE and immunohistochemical staining sections.

Exclusion criteria

Exclusion criteria: Nil

Design outcomes

Primary

MeasureTime frame
SEN, SPE, ACC, AUC of ROC;gene expression profile;gene methylation profile;high throughput sequencing of all exons;—

Countries

China

Contacts

Public ContactWang Jian

Fudan University Shanghai Cancer Center

softtissuetumor@163.com+86 18017312051

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026